title: Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison.
abstract: OBJECTIVE
  Several classes of medications have demonstrated efficacy in panic disorder, but direct comparison of 2 proven treatments is still uncommon. The purpose of this study was to compare sertraline and paroxetine in the acute treatment of panic disorder.
  
  
  METHODS
  Adult outpatients with panic disorder with or without agoraphobia (DSM-IV and ICD-10 criteria) were randomly assigned in double-blind fashion to 12 weeks of treatment with flexible doses of sertraline (titrated up to 50-150 mg/day; N = 112) or paroxetine (titrated up to 40-60 mg/day; N = 113). Patients were then tapered off medication over 3 weeks. The primary analysis was a noninferiority analysis of Panic and Agoraphobia Scale (PAS) scores. Secondary measures included panic attack frequency and the Clinical Global Impressions-Improvement scale (CGI-I) (with responders defined as those with a CGI-I score < or = 2). Data were collected from January 2000 to June 2001.
  
  
  RESULTS
  Sertraline and paroxetine were associated with equivalent levels of improvement on the PAS total score, as well as on all secondary outcome measures. Eighty-two percent of patients taking sertraline versus 78% of those taking paroxetine were CGI-I responders at endpoint. Numerically more patients on paroxetine treatment compared with sertraline treatment discontinued due to adverse events (18% vs. 12%; NS), and a significantly higher proportion of paroxetine patients showed > or = 7% weight gain (7% vs. < 1%; p <.05). During the taper period, the proportion of panic-free patients increased by 4% with sertraline but decreased by 11% with paroxetine (p <.05).
  
  
  CONCLUSIONS
  Sertraline and paroxetine had equivalent efficacy in panic disorder, but sertraline was significantly better tolerated and was associated with significantly less clinical worsening during taper than paroxetine.
authors.affiliation: Department of Psychiatry and Psychotherapy, University of Göttingen, von-Siebold-Strasse 5, D-37505 Göttingen, Germany. bbandel@gwdg.de
authors.forename: Borwin
authors.initials: B
authors.lastname: Bandelow
authors.forename: Kirsten
authors.initials: K
authors.lastname: Behnke
authors.forename: Sergio
authors.initials: S
authors.lastname: Lenoir
authors.forename: G J
authors.initials: GJ
authors.lastname: Hendriks
authors.forename: Tunc
authors.initials: T
authors.lastname: Alkin
authors.forename: Claus
authors.initials: C
authors.lastname: Goebel
authors.forename: Cathryn M
authors.initials: CM
authors.lastname: Clary
mesh_terms: D000208:Acute Disease; D000328:Adult; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000188:drug therapy*; D017374:Paroxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020280:Sertraline / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline